Strong half-year 09/10 financial results from Australia's CSL and Biota
Australian plasma specialist firm CSL has announced a profit after tax of A$617 million ($554.1 million) for the six months ended December 31, 2009, up 23% on the like, year earlier period. Also yesterday, compatriot Biota Holdings posted a whacking 364% leap in net profits to a record $33.5 million for the half-year.
CSL said its result included an unfavorable foreign exchange impact of A$46 million, adjusting for which net profit after tax grew 32%. Total sales revenue of A$2.3 billion rose 5%, up 12% at constant currency, the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze